See the source imageWomen diagnosed with breast or gynecologic cancers underutilized both assisted reproductive technology and fertility-sparing oncology care, according to study results.

The findings, presented during the Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, additionally showed that women residing in urban vs. rural areas and those with private insurance vs. Medicaid used assisted reproductive technology and fertility-sparing oncology care more frequently, regardless of cancer type.

Two beneficial approaches to preserve fertility are available for women diagnosed with breast or gynecologic cancers, including assisted reproductive technology — medical treatments or procedures that handle eggs and sperm to address infertility — and fertility-sparing oncology care — surgical or medical interventions that retain the uterus and at least one ovary for gynecologic cancers, according to study background.

However, research is limited on the association between sociodemographic characteristics and the use of assisted reproductive technology or receipt of fertility-sparing oncology care among women with a history of gynecologic or breast cancers, Kirsten Jorgensen, MD, a fellow in the department of gynecologic oncology at The University of Texas MD Anderson Cancer Center, and colleagues wrote.

readmore…